It is amazing how far LAM research has come in such a short period of time. Many researchers who have received funding from The LAM Foundation have helped to make this disease a research priority. LAM and TSC researchers have identified a wealth of potential molecular targets and experimental therapies that may be appropriate for testing in clinical trials. Many of these drugs are FDA-approved or in development for other indications.
The LAM Foundation has committed over $11 million to LAM research to support 119 peer-reviewed grants and other research projects for the study of lymphangioleiomyomatosis (LAM). Scientists funded by The LAM Foundation reported numerous breakthroughs, resulting in the first-ever LAM treatment trial to test a drug called sirolimus, or rapamycin, which proved to be an effective treatment for LAM (results published in the April 2011 issue of the New England Journal of Medicine (NEJM). Additional clinical trials are underway as LAM Foundation-funded researchers continue to work with urgency in search of more safe and effective treatments.